Phenotypic expression in von Hippel-Lindau disease: correlations with germline VHL gene mutations.

E R Maher, A R Webster, F M Richards, J S Green, P A Crossey, S J Payne, A T Moore

Cambridge University Department of Pathology, UK.

Von Hippel-Lindau disease is an autosomal dominantly inherited familial cancer syndrome predisposing to retinal and central nervous system haemangioblastomas, renal cell carcinoma, and phaeochromocytoma. VHL disease shows variable expression and interfamilial differences in predisposition to phaeochromocytoma. In a previous study of 65 VHL kindreds with defined VHL mutations we detected significant differences between VHL families with and without phaeochromocytoma such that missense mutations were more common and large deletions or protein truncating mutations less frequent in phaeochromocytoma positive families. To investigate the significance and cause of this association further, we studied 138 VHL kindreds for germline mutations and calculated the age related tumour risks for different classes of VHL gene mutations. Using SSCP, heteroduplex and Southern analysis we identified a germline VHL gene mutation in 101 families (73%). Direct sequencing of the VHL coding region further increased the mutation detection rate to 81%. In addition to precise presymptomatic diagnosis, identification of a VHL gene mutation can provide an indication of the likely phenotype. We found that large deletions and mutations predicted to cause a truncated protein were associated with a lower risk of phaeochromocytoma (6% and 9% at 30 and 50 years, respectively) than missense mutations (40% and 59%, respectively) and that missense mutations at codon 167 were associated with a high risk of phaeochromocytoma (53% and 82% at ages 30 and 50 years). Cumulative probabilities of renal cell carcinoma did not differ between the two groups (deletion/ truncation mutations: 8% and 60%, and missense mutations: 10% and 64% at ages 30 and 50 years, respectively). Age related risks for haemangioblastoma were similar in the two mutation groups, with the age related risks of cerebellar haemangioblastoma slightly less (35% and 64% v 38% and 75% at ages 30 and 50 years) and retinal haemangioblastoma slightly higher (45% and 72% v 37% and 64% at ages 30 and 50 years) in the missense mutation group than in the deletion/protein truncation group. These results provide valuable data for counselling VHL families and indicate that specific VHL mutations may be associated with different tumour susceptibility risks. There was no evidence of a generalised increase in age related tumour risks for missense mutations, suggesting that missense mutations predisposing to phaeochromocytoma have tissue specific effects, possibly because the VHL protein has several functions, the importance of which varies from tissue to tissue, or because the proteins which interact with VHL differ between different tissues.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Article

Risk of multisystem disease in isolated ocular angioma (haemangioblastoma)

ANDREW R WEBSTER, EAMONN R MAHER, ALAN C BIRD, ANTHONY T MOORE
J. Med. Genet. 2000 37: 62-63. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Gergics, P., Patocs, A., Toth, M., Igaz, P., Szucs, N., Liko, I., Fazakas, F., Szabo, I., Kovacs, B., Glaz, E., Racz, K. (2009). Germline VHL gene mutations in Hungarian families with von Hippel-Lindau disease and patients with apparently sporadic unilateral pheochromocytomas. Eur J Endocrinol 161: 495-502 [Abstract] [Full Text]  
• Vanneste, E., Melotte, C., Debrock, S., D'Hooghe, T., Brems, H., Fryns, J.P., Legius, E., Vermeesch, J.R. (2009). Preimplantation genetic diagnosis using fluorescent in situ hybridization for cancer predisposition syndromes caused by microdeletions. Hum Reprod 24: 1522-1528 [Abstract] [Full Text]  
• Karagiannis, A., Mikhailidis, D. P, Athyros, V. G, Harsoulis, F. (2007). Pheochromocytoma: an update on genetics and management. Endocr Relat Cancer 14: 935-956 [Abstract] [Full Text]  
• Woodward, E. R., Wall, K., Forsyth, J., Macdonald, F., Maher, E. R. (2007). VHL mutation analysis in patients with isolated central nervous system haemangioblastoma. Brain 130: 836-842 [Abstract] [Full Text]  
• Jimenez, C., Cote, G., Arnold, A., Gagel, R. F. (2006). Should Patients with Apparently Sporadic Pheochromocytomas or Paragangliomas be Screened for Hereditary Syndromes?. J. Clin. Endocrinol. Metab. 91: 2851-2858 [Abstract] [Full Text]  
• Woodward, E. R, Maher, E. R (2006). Von Hippel-Lindau disease and endocrine tumour susceptibility.. Endocr Relat Cancer 13: 415-425 [Abstract] [Full Text]  
• Maher, E. R. (2006). Genetics of phaeochromocytoma. Br Med Bull 79-80: 141-151 [Abstract] [Full Text]  
• Cascon, A, Ruiz-Llorente, S, Fraga, M F, Leton, R, Telleria, D, Sastre, J, Jose Diez, J, Martinez Diaz-Guerra, G, Diaz Perez, J A, Benitez, J, Esteller, M, Robledo, M (2004). Genetic and epigenetic profile of sporadic pheochromocytomas. J. Med. Genet. 41: e30-30 [Full Text]  
• Rocha, J C C, Silva, R L A, Mendonca, B B, Marui, S, Simpson, A J G, Camargo, A A (2003). High frequency of novel germline mutations in the VHL gene in the heterogeneous population of Brazil. J. Med. Genet. 40: e31-31 [Full Text]  
• Cascon, A, Cebrian, A, Ruiz-Llorente, S, Telleria, D, Benitez, J, Robledo, M (2002). SDHB mutation analysis in familial and sporadic phaeochromocytoma identifies a novel mutation. J. Med. Genet. 39: e64-64 [Full Text]  
• Cybulski, C, Krzystolik, K, Murgia, A, Gorski, B, Debniak, T, Jakubowska, A, Martella, M, Kurzawski, G, Prost, M, Kojder, I, Limon, J, Nowacki, P, Sagan, L, Bialas, B, Kaluza, J, Zdunek, M, Omulecka, A, Jaskolski, D, Kostyk, E, Koraszewska-Matuszewska, B, Haus, O, Janiszewska, H, Pecold, K, Starzycka, M, Slomski, R, Cwirko, M, Sikorski, A, Gliniewicz, B, Cyrylowski, L, Fiszer-Maliszewska, L, Gronwald, J, Toloczko-Grabarek, A, Zajaczek, S, Lubinski, J (2002). Germline mutations in the von Hippel-Lindau (VHL) gene in patients from Poland: disease presentation in patients with deletions of the entire VHL gene. J. Med. Genet. 39: e38-38 [Full Text]  
• Allen, R. C., Webster, A. R., Sui, R., Brown, J., Taylor, C. M., Stone, E. M. (2001). Molecular Characterization and Ophthalmic Investigation of a Large Family With Type 2A von Hippel-Lindau Disease. Arch Ophthalmol 119: 1659-1665 [Abstract] [Full Text]  
• Bender, B. U, Eng, C., Olschewski, M., Berger, D. P, Laubenberger, J., Altehofer, C., Kirste, G., Orszagh, M., van Velthoven, V., Miosczka, H., Schmidt, D., Neumann, H. P H (2001). VHL c.505 T>C mutation confers a high age related penetrance but no increased overall mortality. J. Med. Genet. 38: 508-514 [Abstract] [Full Text]  
• Hoffman, M. A., Ohh, M., Yang, H., Klco, J. M., Ivan, M., Kaelin, W. G. Jr (2001). von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum Mol Genet 10: 1019-1027 [Abstract] [Full Text]  
• Clifford, S. C., Cockman, M. E., Smallwood, A. C., Mole, D. R., Woodward, E. R., Maxwell, P. H., Ratcliffe, P. J., Maher, E. R. (2001). Contrasting effects on HIF-1{{alpha}} regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum Mol Genet 10: 1029-1038 [Abstract] [Full Text]  
• STRIZHEVA, G. D., CARSILLO, T., KRUGER, W. D., SULLIVAN, E. J., RYU, J. H., HENSKE, E. P. (2001). The Spectrum of Mutations in TSC1 and TSC2 in Women with Tuberous Sclerosis and Lymphangiomyomatosis. Am. J. Respir. Crit. Care Med. 163: 253-258 [Abstract] [Full Text]  
• Beales, P. L., Reid, H. A.S., Griffiths, M. H., Maher, E. R., Flinter, F. A., Woolf, A. S. (2000). Renal cancer and malformations in relatives of patients with Bardet-Biedl syndrome. Nephrol Dial Transplant 15: 1977-1985 [Abstract] [Full Text]  
• Hes, F J, McKee, S, Taphoorn, M J B, Rehal, P, van der Luijt, R B, McMahon, R, van der Smagt, J J, Dow, D, Zewald, R A, Whittaker, J, Lips, C J M, MacDonald, F, Pearson, P L, Maher, E R (2000). Cryptic von Hippel-Lindau disease: germline mutations in patients with haemangioblastoma only. J. Med. Genet. 37: 939-943 [Abstract] [Full Text]  
• Woodward, E. R, Clifford, S. C, Astuti, D., Affara, N. A, Maher, E. R (2000). Familial clear cell renal cell carcinoma (FCRC): clinical features and mutation analysis of the VHL, MET, and CUL2 candidate genes. J. Med. Genet. 37: 348-353 [Abstract] [Full Text]  
• WEBSTER, A. R, MAHER, E. R, BIRD, A. C, MOORE, A. T (2000). Risk of multisystem disease in isolated ocular angioma (haemangioblastoma). J. Med. Genet. 37: 62-63 [Full Text]  
• Pack, S. D., Zbar, B., Pak, E., Ault, D. O., Humphrey, J. S., Pham, T., Hurley, K., Weil, R. J., Park, W.-S., Kuzmin, I., Stolle, C., Glenn, G., Liotta, L. A., Lerman, M. I., D., R., W., K., Linehan, M., Zhuang, Z. (1999). Constitutional von Hippel-Lindau (VHL) Gene Deletions Detected in VHL Families by Fluorescence in Situ Hybridization. Cancer Res. 59: 5560-5564 [Abstract] [Full Text]  
• Kroll, S. L., Paulding, W. R., Schnell, P. O., Barton, M. C., Conaway, J.W., Conaway, R. C., Czyzyk-Krzeska, M. F. (1999). von Hippel-Lindau Protein Induces Hypoxia-regulated Arrest of Tyrosine Hydroxylase Transcript Elongation in Pheochromocytoma Cells. J. Biol. Chem. 274: 30109-30114 [Abstract] [Full Text]  
• Roach, E. S. (1999). Von Hippel-Lindau disease. Neurology 53: 7-7 [Full Text]  
• Webster, A. R., Maher, E. R., Moore, A. T. (1999). Clinical Characteristics of Ocular Angiomatosis in von Hippel-Lindau Disease and Correlation With Germline Mutation. Arch Ophthalmol 117: 371-378 [Abstract] [Full Text]  
• Webster, A. R, Fisher, R. B, Ginsberg, L., Maher, E. R (1997). Independent segregation of von Hippel-Lindau disease and cerebral cavernomas. J. Neurol. Neurosurg. Psychiatry 63: 665-668 [Abstract] [Full Text]